We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Development and clinical utility of abiraterone acetate as an androgen synthesis inhibitor.
- Authors
Bryce, A; Ryan, C J
- Abstract
In April 2011, abiraterone acetate (AA) was approved by the US Food and Drug Administration (FDA) for the treatment of metastatic castration-resistant prostate cancer (CRPC) after chemotherapy. The development of AA is the direct result of our increased understanding of the intricacies of the androgen receptor (AR) pathway and its natural evolution in prostate cancer cells over the course of treatment. In this paper we review the biology of the AR and how it led to the rational design of AA. We also examine the clinical development of AA, its current use, and questions to be addressed for future development.
- Publication
Clinical pharmacology and therapeutics, 2012, Vol 91, Issue 1, p101
- ISSN
1532-6535
- Publication type
Journal Article
- DOI
10.1038/clpt.2011.275